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Abstract  
 
Human melanomas exhibit relatively high somatic mutation burden compared to other 
malignancies. These somatic mutations may produce neoantigens that are recognized by the 
immune system, leading to an anti-tumor response. By irradiating a parental mouse 
melanoma cell line carrying three driver mutations with UVB and expanding a single cell-
derived clone, we generated a mutagenized model that exhibits high somatic mutation 
burden. When inoculated at low cell numbers in immunocompetent C57BL/6J mice, 
YUMMER1.7 (YUMM Exposed to Radiation) regresses after a brief period of growth. This 
regression phenotype is dependent on T cells as YUMMER1.7 tumors grow significantly 
faster in immunodeficient Rag1-/- mice and C57BL/6J mice depleted of CD4 and CD8 T 
cells. Interestingly, regression can be overcome by injecting higher cell numbers of 
YUMMER1.7, which results in tumors that grow without effective rejection. Mice that have 
previously rejected YUMMER1.7 tumors develop immunity against higher doses of 
YUMMER1.7 tumor challenge. Additionally, escaping YUMMER1.7 tumors are sensitive to 
anti-CTLA-4 and anti-PD-1 therapy, establishing a new model for the evaluation of anti-
tumor immune responses and novel therapeutics.  
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Introduction  
 
 
Mutational Landscape of Melanoma  
During the year of Napoleon’s Prussian Campaign in 1806, René Laennec provided 
the first description of melanoma as a disease in an unpublished memoir to the Faculté de 
Médecine in Paris (1). The first to use the word “melanoma,” Laennec noted that this disease 
caused metastases in the mediastinal and hilar lymph nodes, which differed from bronchial 
glands blackened by carbon deposition. In 1820, William Norris made several observations 
about the possible genetic basis of melanoma: “it is remarkable that this gentleman’s 
father…died of a similar disease. This tumor…originated in a mole and it is also worth 
mentioning that, not only my patient and his children had many moles…but also his own 
father and brothers…These facts…would incline me to believe that this disease is hereditary” 
(2). Since then, the neural crest-derived melanocyte has been identified as the cell of origin 
of melanoma, and breakthroughs have led to a fundamental understanding of the molecular 
drivers of melanoma.  
Indeed, a proportion of melanomas are hereditary as evidenced by patients with 
familial atypical mole/melanoma syndrome (FAMM). In 1992, mutations in the CDKN2A 
gene were reported in a subset of kindreds with FAMM (3). This high-penetrance 
susceptibility gene locus encodes for two proteins, p16 and p14ARF, which regulate cell cycle 
progression through the retinoblastoma and p53 pathways, respectively. In families, carriers 
of the CDKN2A mutation have an estimated risk of 30% to develop melanoma by age 50 and 
67% by age 80 (4). In contrast to this high-risk allele, loss-of-function mutations in 
melanocortin 1 receptor (MC1R) modestly increase the susceptibility to melanoma in the 
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broader population with light complexion, red hair and blue eyes. UV irradiated 
keratinocytes secrete α-melanocyte stimulating hormone (αMSH), which binds to MC1R on 
melanocytes. MC1R activation of microphthalmia-associated transcription factor (MITF) 
induces melanocytes to produce brown/black eumelanin and red pheomelanin. Eumelanin 
protects against UV radiation, but pheomelanin can actually contribute to melanomagenesis 
through the production of reactive oxygen species (ROS) (5). Fair skin and red hair 
individuals with mutations in MC1R synthesize greater levels of pheomelanin compared to 
eumelanin and are at greater risk for melanoma development.  
Other driver mutations known to induce carcinogenesis have been elucidated in 
melanoma. BRAF mutations occur in over 80% of melanocytic nevi and the valine-to-
glutamic acid substitution at codon 600 is found in approximately 50% of melanomas (6). 
Although recent studies corroborate the role of ultraviolet radiation in all evolutionary stages 
of melanoma, BRAFV600E mutations are usually caused by T->A transversions, not typical of 
UV radiation (7, 8). BRAFV600E could be a direct but rare byproduct of UV radiation caused 
by error-prone DNA polymerases or the result of another mutagenic mechanism. Although a 
BRAF mutation alone typically is associated with benign melanocytic nevus formation and 
does not lead to malignant transformation, other genetic alterations cooperate with BRAF 
activation to induce melanomas. For instance, BrafV600E alone caused benign melanocytic 
hyperplasia, but rapidly resulted in melanoma when combined with Pten loss in a murine 
model (9). PTEN acts as a tumor suppressor by encoding a protein phosphatase that 
negatively regulates the PI3K/AKT pathway through its action on phosphatidylinositol 
phosphate (PIP3). PI3K signaling promotes cell growth and survival. Loss of PTEN occurs in 
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20-30% of melanoma tumors. Similarly, MITF is also a melanoma oncogene that can 
transform melanocytes in conjunction with BRAFV600E (10).  
Additional driver mutations in melanoma include alterations in RAS proteins such as 
NRAS, KRAS and HRAS as well as c-KIT, which is the receptor tyrosine kinase for stem 
cell factor (SCF). These mutations are associated with different forms of clinical melanoma. 
For instance, BRAF and NRAS mutations are commonly found in superficial spreading and 
nodular melanoma while acral lentiginous melanomas generally harbor changes in KIT. 
Moreover, chronically sun-exposed melanomas are associated with BRAFnonV600E, NRAS or 
NF1 mutations whereas non-chronically sun-exposed melanomas affect younger individuals 
and are often driven by BRAFV600E mutations (11). Contrastingly, uveal melanomas possess 
activating mutations in GNAQ and GNA11, which are also involved in MAPK signaling.  
Compared to other cancer types, melanomas exhibit high rates of somatic mutations. 
Primary and metastatic melanomas are among the most highly mutated tumors analyzed by 
the Cancer Genome Atlas with a reported mean mutation rate of 16.8 mutations/Mb per 
exome (12). Primary melanomas generally carry more than one hundred nonsynonymous 
coding mutations per tumor (13). Accompanying driver mutations are a large number of 
passenger mutations that do not confer a selective growth advantage (14). The vast majority 
of these passenger mutations show a predominant UV signature (C -> T transitions at 
dipyrimidine sites) in melanoma.  
Because passenger mutations dominate the melanoma genome landscape, they have 
the greatest potential to produce peptide epitopes that act as neoantigens and elicit anti-tumor 
immune responses (15). Distinct from the class of non-mutated “self-antigens” such as 
MAGE antigens and Melan-A/MART-1, neoantigen recognition by T cells is not affected by 
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central tolerance. However, the understanding of neoantigens has been limited by the fact 
that most are unique to each tumor. In a study of eight CD4 T cell neoantigens and thirteen 
CD8 T cell neoantigens, 20/21 epitopes were found in only one tumor from a cohort of 
approximately 20,000 human tumor samples (16). Nevertheless, high-throughput sequencing 
technologies now permit the identification of potential neoantigens on an individual basis. 
This is achieved by predicting major histocompatibility complex (MHC) binding peptides 
from nonsynonymous exonic mutations unique to the tumor and assessing for T cell 
reactivity. Predicted peptides can be filtered for expression and further prioritized based on 
likelihood of proteasomal processing, transport into the endoplasmic reticulum, affinity for 
MHC class I and II alleles and immunogenicity (based on the type of residues exposed to T 
cell receptors). While in silico methods of predicting neoepitopes have improved markedly, 
experimental validation is still required to confirm specific neoepitopes. Therapeutics to 
stimulate neoantigen-specific T cell responses using checkpoint blocking antibodies, 
oncolytic viruses or synthetic vaccines are of great interest.  
 
Immunotherapy in Melanoma  
As the most deadly form of skin cancer, melanoma caused 9,710 deaths in the United 
States in 2014 (17). Until recently, systemic therapy failed to significantly prolong survival 
in advanced stage melanoma patients. The FDA approved dacarbazine in 1975, but the 
alkylating chemotherapy resulted in only partial responses with median survival ranging 
from 5-11 months, similar to untreated control patients. Next, targeted therapies aimed at 
BRAF V600E patients improved response rates significantly. A randomized phase III trial 
showed that vemurafenib increased overall response rates to 48% compared to 5% for 
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dacarbazine (18). Subsequently, vemurafenib and dabrafenib, two BRAF inhibitors, were 
approved in 2011 and 2013, respectively. Unfortunately, despite high response rates, targeted 
therapies exhibit limited durability because of drug resistance. Mechanisms of resistance 
include reactivation of MAPK signaling through MEK1-activating mutations, NRAS 
mutations, loss of NF1 or upregulation of PI3K signaling. BRAF inhibitors are now given in 
combination with MEK inhibitors to combat resistance and overcome paradoxical 
hyperactivation of CRAF in cells containing wild-type BRAF, which causes 
hyperproliferation of keratinocytes and low-grade squamous cell carcinomas. Nonetheless, 
the median progression-free survival for BRAF and MEK inhibitors remains only five to 
seven months (19). 
 In contrast, immunotherapy has demonstrated promising efficacy in advanced 
melanoma with a proportion of patients experiencing long-term survival. The first 
immunotherapy to be approved for metastatic melanoma was high dose interleukin-2 in 
1998, which produced only an overall objective response rate of 16% and was associated 
with significant toxicities (20). Subsequently, checkpoint inhibitors, which block inhibitory 
pathways affecting T cell responses, achieved greater success. Activation of naïve T cells 
requires not only recognition of the MHC-peptide complex by the T cell receptor (TCR) but 
also costimulation, which amplifies TCR signaling. One costimulatory molecule on T cells is 
CD28, which binds B7 molecules (CD80 and CD86) on antigen-presenting cells. 
Contrastingly, cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 
(PD-1) are inhibitory T cell receptors that suppress immune responses and play a role in 
tolerance. Tumors may be able to evade immunosurveillance by taking advantage of these 
two “brakes.”  
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 CTLA-4 counteracts the early stages of T cell activation by binding B7 molecules 
with much higher affinity than CD28, thereby blocking costimulation (21, 22). CTLA-4 is 
also a target of the Forkhead Box P3 transcription factor (FOXP3), which determines the cell 
lineage of regulatory T cells. Thus, CTLA-4 may also enhance the immunosuppressive 
effects of regulatory T cells (23). These studies led to the development of ipilimumab, a 
monoclonal antibody (IgG1) against CTLA-4. In a landmark phase III clinical trial, 
metastatic melanoma patients treated with ipilimumab exhibited a median overall survival of 
10.1 months compared with 6.4 months among patients receiving the cancer vaccine 
glycoprotein 100 (24). More importantly, in the 15 patients who had a partial or complete 
response, 9 maintained the response for at least 2 years. Grade 3 or 4 immune-related adverse 
events usually affecting the skin or gastrointestinal tract did occur in 10-15% of patients on 
ipilimumab including 7 associated deaths. But the durability of response to ipilimumab from 
this trial led to its approval in 2011. Since then, long-term responses to this therapy have 
been observed in approximately 20% of treated patients.  
 While both interfere with T cell responses, the mechanisms of PD-1 and CTLA-4 
action differ significantly. Whereas anti-CTLA-4 promotes broad T cell activation that may 
not be specific for tumor antigens, anti-PD-1 targets effector T cell activity in peripheral, 
inflamed tissues because PD-1 ligands have limited distribution in normal tissues. Its major 
ligand, PD-L1, is expressed on tumor cells and other cells of the tumor microenvironment 
after exposure to T cells that secrete the cytokine interferon-γ (IFN- γ). For this reason, it is 
believed that PD-L1 is upregulated in response to cancer-induced inflammation, serving as 
negative feedback to quell immune responses. Such a regulatory system limits tissue damage 
during inflammation but also hinders tumor immunity (25). Altogether, data suggest that 
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anti-PD-1 therapy would induce less autoimmune toxicity than anti-CTLA-4. For this reason, 
clinical testing with PD-1 inhibitors was pursued.  
Two human antibodies targeting PD-1, pembrolizumab and nivolumab, have 
demonstrated improved response rates in melanoma with less toxicity than ipilimumab. In a 
trial comparing nivolumab and dacarbazine, 40.0% of advanced melanoma patients treated 
with nivolumab achieved an objective response, significantly higher than the 13.9% response 
rate of patients on dacarbazine (26). The overall survival at 1 year was 72.9% in the 
nivolumab group and 42.1% in the dacarbazine group. Treatment-related adverse events of 
grade 3 or 4 occurred in 11.7% of patients on nivolumab. Likewise, in a head-to-head 
comparison within the KEYNOTE-006 trial, pembrolizumab increased response rates to 
32.9-33.7% (two and three week regimens) from 11.9% with ipilimumab and prolonged 
overall survival (27). One year survival rates were 68.4%-74.1% in the pembrolizumab group 
and 58.2% for the ipilimumab group. Although 80.5% of patients had tumors positive for 
PD-L1 (defined as at least 1% of tumor cells staining positive for membranous PD-L1), the 
benefit of pembrolizumab over ipiliumab was observed in both PD-L1 positive and negative 
subgroups. Grade 3 to 5 adverse events occurred in 10.1-13.3% and 19.9% of patients 
receiving pembrolizumab and ipilimumab, respectively. Both nivolumab and pembrolizumab 
were approved by the FDA in 2014 for metastatic melanoma after progression on ipilimumab 
or a BRAF inhibitor.  
 Since anti-CTLA-4 and anti-PD-1 therapies take advantage of different mechanisms 
of T cell suppression, there was impetus to use them in combination. Indeed, multiple trials 
report the synergistic benefit of this combination in boosting response but at the cost of 
greater toxicities (28, 29). Nivolumab and ipilimumab produced an objective response rate of 
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61% compared to 11% in the ipilimumab group in one study (30). However, drug-related 
adverse events of grade 3 or 4 increased from 24% to 54%. Such events were the most 
common reason (45%) for discontinuation of the combination therapy. Thus, the higher 
response rates of combination treatment must be weighed against its safety profile.  
Although immunotherapy has been successful in treating a variety of tumor types, 
they are particularly efficacious in melanoma. A major reason for this may be the high 
somatic mutation burden characteristic of melanoma (31). This hypothesis is supported by 
the success of a phase 2 clinical trial using PD-1 blockade to treat mismatch repair-deficient 
colorectal and non-colorectal cancers, which have even higher mutation loads than melanoma 
(32). Indeed, greater somatic mutations appear to be associated with improved survival in the 
setting of immune checkpoint blockade (33, 34). McGranahan et al. analyzed 64 melanoma 
patients treated with CTLA-4 antibody. Tumors exhibiting high clonal neoantigen burden 
and low neoantigen intratumoral heterogeneity exhibited significantly improved overall 
survival (35). Additionally, in two patients who responded to anti-CTLA-4 therapy, 
peripheral blood mononuclear cell analysis identified CD8 T cell populations that recognized 
neoantigens present in 100% of cancer cells. They reasoned that neoantigen burden 
influences sensitivity to immunotherapies, but the presence of such neoantigens on most 
tumor cells (homogeneity) is also important in predicting response.   
 
Mouse Models of Melanoma  
Mouse models of melanoma have long been utilized to advance our understanding of 
the disease. The first models were generated spontaneously from inbred mouse strains or 
induced with mutagens such as UV radiation or 7,12-Dimethylbenz(a)anthracene (36). One 
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of the spontaneously arising mouse melanomas first isolated over 86 years ago—the B16 cell 
line—remains widely used today in experimental studies (37). The ease with which it can be 
cultured, manipulated in vitro, and transplanted into congenic mice makes it a tractable 
model to study melanoma biology. Nevertheless, genetic drivers of B16 may not accurately 
reflect those present in human melanoma. Exome sequencing of B16F10 murine melanoma 
cells revealed 962 nonsynonymous somatic point mutation differences compared to the 
background C57BL/6 exome (38). Although homozygous deletion of Cdkn2a and two 
missense mutations in Pten were detected, no mutations were found in Braf, c-Kit, Nras or 
Kras. Furthermore, the study of immune responses generated against B16 tumors is also 
limited by several factors. First, retroviral elements appear to be important for B16 tumor 
formation, thereby confounding the generalizability of the model (39, 40). Also, B16 is 
considered to be poorly immunogenic given its low expression of MHC class I molecules 
(41). In fact, when CTLA-4 blockade was studied in this model, treatments showed little 
effect (42). Only when combined with a granulocyte/macrophage colony-stimulating factor 
(GM-CSF) expressing tumor cell vaccine did treatments induce rejection of the B16 tumors. 
Because of these caveats to B16, improved mouse melanoma models are necessary.  
To accurately model driver mutations, transgenic mouse technology allows for the 
manipulation of molecular pathways commonly defective in melanoma. Genetically 
engineered mice are able to develop tumors through melanocyte-specific activation of the 
Ras or c-Met-HGF/SF signaling axes in combination with changes to cell-cycle control 
elements like p16 or p19. Furthermore, Cre-lox recombination allows the generation of 
conditional alleles, providing greater control over tumor formation. Dankort et al. described a 
mouse melanoma model with a BrafV600E mutation and Pten inactivation, which developed 
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melanomas upon administration of topical 4-hydroxytamoxifen (9). Their construct contained 
wild-type exons 15-18 of human BRAF flanked by loxP sites followed by the mutated exon 
15 after the stop codon. So, when CreER was activated by tamoxifen via a Cre recombinase-
estrogen receptor fusion transgene under the control of a tyrosinase promoter, the human 
exons were removed and the V600E mutated fully murine Braf allele was expressed under 
the control of its endogenous regulatory elements. The Ptenlox/lox alleles conditionally deleted 
either exons 4 and 5 or only exon 5, which are critical for the phosphatase activity of the 
protein product. Although BrafV600E alone caused only benign melanocytic hyperplasia, the 
combination of BrafV600E and Pten silencing induced melanomas with 100% penetrance, no 
measurable latency, remarkable multiplicity, and metastases to the lymph nodes and lungs. 
Like this Braf/Pten model, other genetically engineered mouse models (GEMMs) have been 
created with genetic changes relevant to human melanoma (43, 44). These resources serve as 
valuable tools to study genotype-phenotype correlation.  
To enhance the practicality of GEMMs, the Bosenberg lab has recently generated cell 
lines from genetically distinct melanoma GEMMs (45). Each cell line contains different 
combinations of genetic drivers (Table 1). They eliminate the need to maintain complex 
mouse colonies with the appropriate genotypes and can be implanted into congenic C57BL/6 
mice to form tumors with shorter latency than GEMMs. This series, entitled the Yale 
University Mouse Melanoma (YUMM) cell lines, includes 10 different human-relevant 
genotypes. For example, YUMM1.1 was the first cell line derived from a tumor in a GEMM 
with the conditional alleles BrafV600E/wt, Pten-/-, Cdkn2a-/-. YUMM1.7 has the same genotype 
as YUMM1.1 but was generated from a separate mouse and tumor. When evaluated in vitro 
and in vivo, Braf-driven YUMM lines were growth inhibited by treatment with PLX4720, a 
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Braf inhibitor. PLX4720 chow delayed growth of YUMM1.7 tumors until about day 50, after 
which growth rapidly increased. This demonstrated that the YUMM lines could be used to 
model clinical responses of human melanoma to targeted therapy. The YUMM series has 
been utilized widely and is being distributed by the American Type Culture Collection 
(ATCC) (46-48).  
 The original YUMM lines are only partially immunogenic based on immune 
infiltration, which consisted of mostly F4/80 tumor-associated macrophages and few CD3 T 
cells (45). Moreover, when YUMM1.7 was engrafted into wild-type C57BL/6 and 
immunodeficient Rag1-/- C57BL/6 mice, no significant differences in tumor growth were 
observed. In other words, an intact adaptive immune system did not effectively control tumor 
volume. The minimal immune response generated against these cell lines is likely due to 
their low somatic mutation burden as is the case in GEMMs. The purpose of the following 
work is to build a more immunogenic model using a YUMM cell line in order to retain the 
driver mutations important in human melanoma. Toward this end, we hypothesized that UV-
induced passenger mutations would create additional neoantigens within cell lines and 
stimulate a more robust immune response. We show that a derivative of YUMM1.7 
transformed through UV mutagenesis, YUMMER1.7 (YUMM Exposed to Radiation), indeed 
elicits a functional adaptive immune response dependent on T cells. This model better 
recapitulates the genomic landscape of human melanomas and responds to existing immune 
checkpoint therapies, setting the stage for future evaluation of novel therapeutics.  
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Table 1. Yale University Mouse Melanoma (YUMM) Cell Lines.  
Each cell line family is designated by the first number, which corresponds to a particular 
combination of mutations that drives tumor formation. The second number identifies the 
individual tumor from which each cell line was derived.  
 
 
Cell Line Family 
 
Genotype 
 
Individual Cell Lines 
 
 
YUMM1 
 
BrafV600E/wt, Pten-/-, Cdkn2a-/- 
 
YUMM1.1, 1.2, 1.3, 1.4, 1.5, 
1.6, 1.7, 1.8, 1.9, 1.10, 1.11, 
1.12, 1.13, 1.14, 1.15 
 
YUMM2 BrafV600E/wt, Pten-/-, Cdkn2a-/-
, BcatSTA/wt 
YUMM2.1, 2.2 
 
 
YUMM3 BrafV600E/wt, Cdkn2a-/- YUMM3.1, 3.2, 3.3, 3.4 
 
YUMM4 Pten-/-, Cdkn2a-/- YUMM4.1, 4.2, 4.3, 4.4 
 
YUMM5 BrafV600E/wt, p53-/- YUMM5.1, 5.2, 5.3, 5.4 
 
YUMM6 
 
BrafV600E/wt, Pten-/- YUMM6.1 
YUMM7 BrafV600E/wt, Cdkn2a-/-, 
BcatSTA/wt 
 
Future lines 
YUMM8 
 
BrafV600E/wt, Cdkn2a-/-, 
Lkb1-/- 
 
Future lines 
YUMM9 
 
NrasQ61R, Cdkn2a-/-, Future lines 
YUMM10 
 
NrasQ61R, p53-/- Future lines 
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Hypothesis:  
 
Somatic mutations induced by UV irradiation of a mouse melanoma model elicit a robust T 
cell dependent anti-tumor response that can be modulated with immunotherapeutics.  
 
 
Specific Aims:  
 
Specific Aim 1: Derive a mouse melanoma model with high somatic mutation burden from a 
parental cell line by UV mutagenesis.  
 
Specific Aim 2: Characterize the immune response against the mutagenized melanoma tumor 
model.  
 
Specific Aim 3: Evaluate the responsiveness of the mutagenized melanoma model to immune 
checkpoint blockade.  
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Methods  
 
All procedures, experiments and analyses were conducted by the author unless otherwise 
specified.  
 
Cell lines and tissue culture  
YUMMER1.7 was derived from YUMM1.7, which was generated from a GEMM containing 
the alleles BrafV600E/wt, Pten-/-, Cdkn2a-/- (45). Irradiation of YUMM1.7 included three rounds 
of 1500J/m2 UVB (3W for 500 sec) when cells were 50-70% confluent. Cells were given 
time to recover and proliferate before being re-plated and proceeding to the next UV 
treatment. After the final UV treatment, a single cell was clonally expanded. UV irradiation 
and clonal expansion of the cell line were done by Katrina Meeth. YUMM1.7 and 
YUMMER1.7 DNA content were assessed using a Propidium Iodide Flow Cytometry Kit 
according to manufacturer instructions (Abcam, Cambridge, UK). YUMMER1.7-GFP and 
YUMM1.7-GFP were generated using a P-YUK-GFP plasmid with PiggyBac Transposase 
Expression Vector, a gift from Tian Xu, Department of Genetics, Yale University. 
Transfection was done with Lipofectamine 2000 (Invitrogen, Carlsbad, California) and cells 
were selected using Blastomycin resistance. All cell lines were maintained in DMEM/F12 
media containing 10% FBS, 1% nonessential amino acids and 1% penicillin-streptomycin.  
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In vivo mouse studies 
Four to six week old C57BL/6J mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME) and allowed to acclimate for one week prior to use. C57BL/6J Rag1-/- mice 
were also obtained from the Jackson Laboratory and maintained in our mouse colony. All 
animal experiments protocols were followed according to the Yale Office of Animal 
Research Support Committee guidelines. For tumor inoculation, YUMM1.7 and 
YUMMER1.7 cells were harvested at approximately 60-85% confluence on the day of 
injection. Cells were trypsinized with 0.25% trypsin for approximately 2-3 minutes before 
deactivation with media containing 10% serum. They were then washed twice with sterile 1x 
PBS and counted with an Invitrogen Countess or with a hemocytometer. Cells in 100 µL of 
sterile PBS were injected subcutaneously into a shaved rear flank using a 27G needle. Mice 
were monitored for the appearance of tumor after injection to begin digital caliper 
measurements. Three dimensions were taken for calculation of tumor volume, which was 
calculated using the equation: 0.5233*l*w*h. For depletion experiments, antibodies for CD4 
(GK1.5) and CD8 (TIB210) were made in-house using hydridomas. Mice were injected with 
10 mg/kg of each antibody on day -1 and then twice per week for the course of treatment. 
Loss of CD4 and CD8 T cells were verified by flow cytometry. For immunotherapy 
treatments, anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14), anti-PD-L1 (10F.9G2) antibodies 
were purchased from Bio X Cell (West Lebanon, NH) along with the corresponding isotype 
controls, Syrian Hamster IgG2, Rat IgG2a and Rat IgG2b respectively. Treatments were 
started with palpable tumors at 6 days after initial cell line injections. Mice were given 10 
mg/kg anti-CTLA-4, anti-PD-1 or anti-PD-L1 three times per week for four weeks. CSF-1R 
inhibitor chow (PLX6134, Plexxikon, Berkeley, CA and ResearchDiets, New Brunswick, 
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NJ) was administered at a concentration of 800 mg/kg for the duration of the treatment 
course. Treatments and tumor measurements for the PD-L1 and CSF-1R inhibitor experiment 
were completed by William Damsky.  
 
Histological analysis 
At least three tumors were fixed in 10% formalin for each condition—100,000 cell 
YUMM1.7-GFP, 100,000 cell YUMMER1.7-GFP and 500,000 cell YUMMER1.7-GFP 
tumors at every time point—and embedded in paraffin. Cut sections were stained using GFP 
(Abcam 10558, Cambridge, UK), CD45 (Abcam 290, Cambridge, UK), F4/80 (Thermo 
Fisher 16363, Waltham, MA), CD3 (Biocare Medical 215, Concord, CA), Foxp3 
(eBioscience 145773, San Diego, CA), Cleaved Caspase-3 (Abcam 4051, Cambridge, UK) 
antibodies. Images of representative fields were taken of the tumor types and quantified at 
40X magnification. The positive cells (brown) were counted and compared to the total 
nucleated cells in the field. Five fields were taken per tumor section and averaged.  
 
Flow cytometry analysis 
Single-cell suspensions from tumors or splenocytes were incubated with anti-Fc receptor 
antibody (2.4G2) on ice for 15 minutes in FACS buffer (PBS with 1% FBS and sodium 
azide). The cells were then stained with the appropriate antibodies in 2.4G2-containing 
FACS buffer on ice for 30 minutes. For intracellular cytokine staining, cells were fixed in 
Fix/Perm (eBioscience, San Diego, CA) and stained with antibodies to detect intracellular 
cytokines or transcription factors. All samples were evaluated with LSRII flow cytometers 
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and analyzed with Flowjo (Flowjo, LLC., Ashland, Or). Antibodies against CD45 (A20), 
CD8 (53-6.7) and CD3 (145-2C11) were purchased from eBioscience. Antibodies against 
CD4 (RM4-5), PD-1 (RMP1-14), and TIGIT (1G9) were purchased from Biolegend. 
 
DNA Extraction and Exome Sequencing 
DNA was extracted from YUMM1.7 and YUMMER1.7 cell lines as well as wild-type 
C57BL/6J mouse ears using Qiagen’s DNeasy Blood & Tissue kit (Hilden, Germany). All 
samples passed quality control and were exome sequenced with 100 bp paired end reads 
using Agilent’s SureSelectXT Mouse All Exon kit by Macrogen (Cambridge, MA). Analysis 
of the exome sequencing was conducted by Durga Thakral. Reads were aligned to the mm10 
reference (ftp://ftp-mouse.sanger.ac.uk/ref/GRCm38_68.fa) using BWA version 0.7.15 with 
the –M option. Duplicate reads were marked with Picard version 2.6.0 MarkDuplicates. The 
resulting alignments were subjected to base quality score recalibration in GATK 3.6 using 
the Mus muscularis C57BL/6J SNP and Indel databases according to GATK best practices. 
Variants unique to YUMMER1.7 compared to YUMM1.7 or cell lines compared to wild-
type C57BL/6J were called using GATK MuTect2 with the above mentioned dbsnp and 
mm10 references and were selected for downstream analysis if they passed the default 
MuTect2 filters. Then, variants were annotated using Annovar (2016Feb01 release) with the 
corresponding mm10 ensGene reference according to the program manual. 
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Statistical Analyses 
Unpaired two-tailed t tests and Kaplan-Meier statistical analyses were performed using 
GraphPad Prism (Version 6.0a for Mac OS X, GraphPad Software, La Jolla, CA) using a 
significance cutoff; ns p >0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005. 
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Results  
Specific Aim 1: Derive a mouse melanoma model with high somatic mutation burden from a 
parental cell line by UV mutagenesis.  
 
As a part of the original YUMM series, the YUMM1.7 cell line carries three driver 
mutations: BrafV600E/wt, Pten-/- and Cdkn2a-/-. To generate the mutagenized mouse model, 
YUMMER1.7, YUMM1.7 was exposed to three rounds of UVB radiation (1500 J/m2). After 
the last round of radiation, a single cell-derived clone was selected and expanded (Figure 
1A). 
 In order to characterize the number of UV-induced somatic mutations in 
YUMMER1.7, whole exome sequencing of both the parental YUMM1.7 and mutagenized 
YUMMER1.7 cell lines were performed and compared to the wild-type C57BL/6J exome. 
YUMM1.7 exhibited 310 nonsynonymous exonic point mutations upon comparison to 
C57BL/6J (Table 2), which likely reflects incomplete backcrossing of the four alleles in the 
original genetically engineered mouse model. There were an additional 1446 unique 
nonsynonymous exonic mutations in YUMMER1.7 relative to YUMM1.7. A large 
proportion of these single-base changes (81.5%) were C>T transitions, which is consistent 
with ultraviolet light treatment and mutagenesis (Figure 1B). Upon evaluation of DNA 
content in the cell lines, it was determined that YUMM1.7 contains both diploid and 
tetraploid clones whereas YUMMER1.7 is tetraploid with twice the DNA content as 
splenocytes (Figure 2). Tetraploidy has been reported in melanoma. In one study, 65-90% of 
cells from 8/8 melanoma surgical specimens exhibited tetraploidy as evaluated by in situ 
hybridization (49).  
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Figure 1. Generation and Characterization of YUMMER1.7 Mutations. 
(A) YUMMER1.7 was generated from YUMM1.7 using three rounds of UVB radiation, and 
a single cell-derived clone was expanded. 
(B) Total point mutations in YUMMER1.7 compared to YUMM1.7 categorized based on the 
type of base substitution.  
  
 
 
 
Figure 2. YUMMER1.7 is tetraploid.  
Propidium iodide flow cytometry demonstrates that the vast majority of YUMM1.7 cells 
(orange) are diploid with similar DNA content as splenocytes (red) whereas YUMMER1.7 
(blue) exhibits double the DNA content.  
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Table 2. Mutations between YUMM1.7 and YUMMER1.7 categorized by mutation type 
based on whole exome sequencing. 
 
 Synonymous  
Mutations 
Nonsynonymous  
Mutations 
Other 
MutationsA 
Mutational Load 
(total # of exonic 
mutations) 
YUMM1.7 vs 
C57BL/6J 
 
554 310 17 881 
YUMMER1.7 vs 
C57BL/6J 1457 1731 120 3308 
 
YUMMER1.7 vs 
YUMM1.7  
924 1446 111 2481 
 
AFrameshift indels, nonframeshift indels, stoploss, stopgain 
 
  
	   	   	   	   	  22 	  
Specific Aim 2: Characterize the immune response against the mutagenized melanoma tumor 
model.  
 
In order to understand in vivo growth characteristics of YUMMER1.7 relative to 
YUMM1.7, we subcutaneously implanted 100,000 cells of each model into the flanks of 
C57BL/6J mice and measured tumor volume over time. As expected, YUMM1.7 tumors 
exhibited rapid and continuous growth (Figure 3A). In contrast, YUMMER1.7 cells initially 
grew to a palpable tumor of approximately 10-50 mm3 followed by striking tumor regression 
without regrowth. Clinical regression of YUMMER1.7 melanomas (tumor volume decrease) 
was observed as early as 14 days post-injection, and complete regression was durable for at 
least 120 days.  
Next, we implanted greater numbers of YUMMER1.7 cells in a similar fashion. 
Unlike the 100,000 cell injections, the inoculations of more than 250,000 YUMMER1.7 cells 
resulted in tumors that did not regress and eventually required euthanasia of the mouse, 
suggesting that tumor regression could be overcome by increasing the number of cells 
injected (Figure 3B). To further investigate why inoculation sizes of 100,000 YUMMER1.7 
cells or less leads to tumor regression, we hypothesized that the phenomenon was immune 
mediated. Thus, we injected 100,000 YUMMER1.7 cells into the flanks of immunodeficient 
Rag1-/- mice that lack functional T and B cells. Interestingly, all YUMMER1.7 tumors (5/5) 
in Rag1-/- mice grew without any cases of regression (Figure 3C). Indeed, the YUMMER1.7 
tumors grew at a similar rate compared to the parental model YUMM1.7 tumors. Antibody-
mediated depletion of CD4 and CD8 T cells in wild-type C57BL/6J mice also increased 
tumor growth of YUMMER1.7 when 100,000 cells were injected (Figure 3D). We found that 
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depletion of both CD4 and CD8 T cells significantly accelerated tumor growth compared to 
the isotype control (p = 0.006). These results suggested that tumor regression was the result 
of an adaptive immune response involving both CD4 and CD8 T cells.  
Subsequently, we explored whether mice that had rejected 100,000 cell 
YUMMER1.7 tumors would develop immunity against higher doses of YUMMER1.7 
tumors (Figure 4). We injected 100,000 YUMMER1.7 cells into the right flanks of C57BL/6J 
mice and allowed tumors to completely regress after 30 days. This cohort was then 
rechallenged with 500,000 cell YUMMER1.7 (I + YUMMER1.7) or 500,000 cell YUMM1.7 
(I + YUMM1.7) tumors on the left flanks. All five immunized mice rejected YUMMER1.7 
tumors, whereas none rejected YUMM1.7 tumors. 4/5 tumors grew out in the control naïve 
C57BL/6J mice that were given the same 500,000 cell dose of YUMMER1.7. Interestingly, 
although all YUMM1.7 tumors grew out, the tumors were smaller in the I + YUMM1.7 
group than in the N + YUMM1.7 group, albeit without reaching significance (p = 0.19). 
Finally, antibody-mediated depletion of CD4 and CD8 eliminated the effect of immunization 
as evidenced by 4/4 tumors failing to regress in the I + YUMMER1.7 + anti-CD4/CD8 
group. These observations suggest that mice vaccinated with a low dose of YUMMER1.7 
mounted an adequate T cell memory response to reject a higher burden of YUMMER1.7 
tumors that would otherwise escape immune surveillance in naïve animals. The differences 
in YUMM1.7 tumor sizes in naïve and YUMMER1.7 immunized mice may be attributed to 
an immune response against the shared antigens between the two cell lines.  
In addition, we sought to compare the intratumoral immune infiltration, mitotic rate 
and apoptotic cell death between YUMM1.7 and YUMMER1.7 tumors as a function of time. 
In order to track very early tumors, YUMM1.7 and YUMMER1.7 cell lines were labeled 
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with GFP, implanted and harvested at different time points—day 5, 10, 15, 20, 25 post-
implantation for analysis by immunohistochemistry. Similar to the unlabeled lines, 100,000 
cell YUMM1.7-GFP and 500,000 cell YUMMER1.7-GFP (YUMMER1.7-GFPHI) tumors 
grew out whereas 100,000 cell YUMMER1.7-GFP (YUMMER1.7-GFPLO) tumors regressed 
over time as shown by GFP staining as a percent of nucleated cells (Figure 5A). As a result 
of regression before day 25, staining for YUMMER1.7-GFPLO tumors at day 25 is not 
available. The infiltration of CD45 and CD3 positive nucleated cells increased over time in 
YUMMER1.7-GFPLO tumors whereas the percentage of these cells remained relatively 
constant or decreased in YUMMER1.7-GFPHI and YUMM1.7-GFP tumors (Figure 5A, B). 
At day 20, a period when YUMMER1.7-GFPLO is regressing and YUMMER1.7-GFPHI and 
YUMM1.7-GFP are rapidly expanding, the fraction of CD45 positive nucleated cells were 
significantly greater in YUMMER1.7-GFPLO than YUMMER1.7-GFPHI (p = 0.0045) and  
YUMM1.7-GFP (p = 0.0016) tumors. Similarly, CD3 staining was increased in 
YUMMER1.7-GFPLO tumors compared to YUMMER1.7-GFPHI (p = 0.0141) and 
YUMM1.7-GFP (p = 0.0574) tumors. In YUMMER1.7-GFPLO tumors, although CD3 
infiltration increased over time, the amount of Foxp3 positive staining (a marker of 
immunosuppressive regulatory T cells) remained relatively low. This contrasts with 
increased Foxp3:CD3 ratio over time within YUMMER1.7-GFPHI and YUMM1.7-GFP 
tumors (Figure 5B). Representative images of each cell line and condition are shown for the 
day 20 time point (Figure 5C). Additionally, the mitotic rate was low for all three tumor 
types until day 20, when mitosis markedly increased in YUMMER1.7-GFPHI and 
YUMM1.7-GFP tumors only (Figure 5D). In contrast, cleaved caspase-3 staining, a marker 
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of apoptosis, progressively increased only in YUMMER1.7-GFPLO tumors over time and 
remained low in both types of escaping tumors.  
To further characterize the T cell infiltrate, tumors were harvested from wild-type 
C57BL/6J mice injected with either 500,000 YUMMER1.7 or 500,000 YUMM1.7 cells. 
Tumors were evaluated upon reaching 500-1000 mm3 in volume for flow cytometry analysis 
(between day 30-40). Both CD4 (p = 0.017) and CD8 T cells (p = 0.020) were present at 
significantly higher numbers per gram of tumor in YUMMER1.7 implants compared to 
YUMM1.7 implants (Figure 6). Moreover, tumor-associated YUMMER1.7 CD8 T cells 
expressed increased activation/exhaustion markers such as PD-1 and TIGIT (p = 0.0002).  
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Figure 3. In vivo growth characteristics of YUMM1.7 and YUMMER1.7 in 
immunocompetent and immunodeficient C57BL/6J mice.  
(A) Growth of 100,000 cell YUMM1.7 and YUMMER1.7 tumors engrafted into wild-
type C57BL/6J mice.  
(B) Growth of 100,000, 250,000, 500,000, and 1,000,000 cell YUMMER1.7 tumors 
engrafted into wild-type C57BL/6J mice.  
(C) Growth of 100,000 cell YUMM1.7 tumors and YUMMER1.7 tumors engrafted into 
Rag1-/- C57BL/6J mice.  
(D) Growth of 100,000 cell YUMMER1.7 tumors engrafted into wild-type C57BL/6J 
mice that were treated with depleting antibodies against CD4, CD8 or both.  
Tumor growth curves are representative of two independent experiments (mean ± SEM, 
 N = 5 each).  
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Figure 4. Rejection of tumors with low dose YUMMER1.7 immunizes against tumor 
rechallenge with high dose YUMMER1.7.  
N = naïve C57BL/6J mice, I = C57BL/6J mice injected with 100,000 YUMMER1.7 cells and 
allowed to regress completely for 30 days prior to tumor rechallenge.  
Tumor growth curves are representative of two independent experiments (mean ± SEM, N = 
4-5 each).  
 
Figure 5. Immune infiltration, mitotic rate and apoptotic cell death within YUMM1.7-
GFP and YUMMER1.7-GFP tumors.  
(A) GFP (melanoma), CD45, CD3, F4/80-positive cells as a percent of nucleated cells.  
(B) CD3, Foxp3 as a percent of nucleated cells and Foxp3 as a percentage of CD3 positive 
cells (orange).  
(C) Representative immunohistochemical images of YUMM1.7-GFP and YUMMER1.7-GFP 
tumors on day 20 with the indicated staining at 40X magnification. YRLO = 
YUMMER1.7-GFPLO, YRHI = YUMMER1.7-GFP HI, YM = YUMM1.7-GFP. 
(D) Mitotic rate and cleaved caspase-3 staining for YUMM1.7-GFP and YUMMER1.7-GFP 
tumors over time.  
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For Figure 5A, B, D, data are averages of counts from at least three independent tumors 
(mean ± SEM). 
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Figure 6. Immune infiltration of escaping YUMM1.7 and YUMMER1.7 tumors. 
(A) Density of CD4+ T cells per gram of tumor.  
(B) Density of CD8+ T cells per gram of tumor.  
(C) Percent of CD8+ T cells that are PD1+ TIGIT+. 
500,000 cell YUMM1.7 and YUMMER1.7 tumors were harvested on day 30-40 for analysis 
by flow cytometry. Data are from two independent experiments (N=2-3 each). Mean ± SEM 
are shown.  
∗  p ≤ 0.05, ∗∗∗  p ≤ 0.005. 
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Specific Aim 3: Evaluate the responsiveness of the mutagenized melanoma model to immune 
checkpoint blockade.  
 
Poor immunogenicity of existing syngeneic tumor models has hindered the study and 
evaluation of immunotherapies. We tested the effect of PD-1 and CTLA-4 blockade in the 
500,000 cell YUMMER1.7 model, which would otherwise result in lethal tumor formation. 
All 5 mice in the isotype treated control group progressed to endpoint (tumor volume >1,000 
mm3) by day 32, whereas 4/5 anti-CTLA-4 treated tumors, 2/5 anti-PD-1 treated tumors and 
5/5 combination treated tumors regressed completely (Figure 7A). When regression was 
complete, no tumors regrew for at least 180 days even after treatment was stopped. The one 
tumor in the anti-CTLA-4 treatment group that grew out was slowed by the therapy such that 
it did not reach endpoint until day 78 (Figure 7B). Both anti-CTLA-4 (p = 0.0034) and anti-
PD-1 (p = 0.0119) treatments significantly delayed the progression of YUMMER1.7 tumors 
from 500,000 cell inoculations compared to the isotype control. Similarly, the combination of 
the two checkpoint inhibitors inhibited tumor growth versus isotype control (p = 0.0034). 
When single and combination treatments were compared against each other, only the PD-1 
versus combination treatment comparison was borderline significant (p = 0.0494) in these 
small experimental groups. These effects were not seen in 500,000 cell YUMM1.7 tumors as 
combination treated tumors did not significantly differ in size from isotype antibody control 
treated tumors (Figure 7C).   
 The success of immune checkpoint blockade in the YUMMER1.7 model motivated 
us to test additional immunotherapy combinations. To overcome non-responsiveness or 
resistance to PD-1/PD-L1 inhibitors observed in patients, one approach is to target 
immunosuppressive tumor-associated macrophages. Indeed, in both the YUMM and 
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YUMMER1.7 models, F4/80+ macrophages comprise a large percentage of CD45+ 
hematopoietic cells within the tumor microenvironment. Thus, we treated 500,000 cell 
YUMMER1.7 tumors with anti-PD-L1, CSF-1R inhibitor or the combination of both (Figure 
8). Preliminary experiments indicate that CSF-1R inhibitor enhances the anti-tumor effect of 
anti-PD-L1. Whereas 2/4 anti-PD-L1 treated tumors were growth delayed (no regression), 
2/3 combination treated tumors regressed completely. CSF-1R inhibitor alone did not 
significantly delay tumor growth compared to the control group. These results illustrate the 
utility of YUMMER1.7 to provide preclinical rationale for novel therapeutics.   
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Figure 7. YUMMER1.7 but not YUMM1.7, is sensitive to checkpoint inhibitors anti-
CTLA-4 and anti-PD-1. 
(A) Individual tumor growth curves for YUMMER1.7 tumors treated with anti-CTLA-4, anti-
PD-1 or both compared to isotype control. Data are representative of two independent 
experiments (N = 4-5).  
(B) Kaplan-Meier survival curves for YUMMER1.7 and (C) YUMM1.7 treated tumors with 
an endpoint of tumor size >1000 mm3 (N = 4-5).  
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Figure 8. Combined inhibition of CSF-1R and PD-L1 is superior to either treatment 
alone in YUMMER1.7.  
Individual tumor growth curves for YUMMER1.7 tumors treated with anti-PD-L1, CSF-1R inhibitor 
or both compared to control. Preliminary data from one experiment (N = 3-5). 
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Discussion  
 
 
Mouse models of cancer have been a tremendous resource for studying the biology of 
human malignancies (50). Although fundamental differences exist between species 
particularly with respect to immune function, progress in genetic engineering has helped 
improve models to more accurately reflect disease and the human host (51). Here, we 
describe the generation of a cell line designed to closely model the genomic features of 
human melanoma including common driver mutations and the high burden of passenger 
mutations. Since low somatic mutation burden in many mouse models can limit tumor 
immune responses and the study of immunotherapy, increasing antigen burden by UV 
irradiation was an important element in creating YUMMER1.7 (52). Unlike the parental 
YUMM1.7, which exhibits similar growth in the presence or absence of a functional adaptive 
immune system, YUMMER1.7 elicits a robust immune response as demonstrated by the 
quantity and quality of immune infiltration (45). More importantly, the difference in growth 
kinetics of YUMMER1.7 tumors in wild-type, Rag1-/- and T cell-depleted C57BL/6J mice 
suggests that the adaptive immune system may be responsible for YUMMER1.7 tumor 
regression when 100,000 or fewer cells are injected. What’s more, this immune response 
confers protection against future rechallenge of high doses of YUMMER1.7 in vaccinated 
mice, likely a manifestation of T cell memory.   
The phenotype of YUMMER1.7 tumor growth depends on the initial inoculation cell 
number. In contrast to inoculation cell numbers of 100,000 or less, when 250,000 or more 
cells are implanted, tumors grow out. Potentially, the increased inoculation cell number 
allows the mitotic rate of cancer cells to outpace or otherwise evade the developing immune 
response. Another possibility is that persistently high antigen levels in the context of sub-
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optimal co-stimulation may lead to an anergic or exhausted T cell phenotype analogous to 
what has been reported in mice infected with chronic lymphocytic choriomeningitis virus 
(53). Furthermore, regulatory T cells may play a functional role as we observed that 
regressing tumors are characterized by lower Foxp3:CD3 ratios by IHC compared to tumors 
that grow out (Figure 2B). The Foxp3:CD3 ratio may be increased by indole 2,3-dioxygenase 
(IDO), which is known to promote conversion of naïve T cells to regulatory T cells and can 
be expressed by dendritic cells, myeloid derived suppressor cells and cancer cells (54). 
Reducing the regulatory T cell subset through an IDO inhibitor (1-methyl-D-tryptophan) or 
engraftment into Foxp3DTR mice may reduce the growth of YUMM1.7 and YUMMER1.7 
tumors (55).  
Despite the escape from regression, the 500,000 cell YUMMER1.7 tumors continue 
to be infiltrated by a significantly larger numbers of CD4 and CD8 T cells when compared to 
YUMM1.7 tumors. One possible explanation for this difference is that YUMMER1.7 
neoantigens are more immunogenic than YUMM1.7 tumors. Indeed, the identification of 
neoantigens that elicit this immune response in this model is of great interest. Through 
exome sequencing and peptide prediction algorithms such as NetMHC, we have begun 
generating and ranking neoantigens based on affinity for the C57BL/6J MHC class I 
molecules, H-2Db and H-2Kb (56). T cells reactive against neoantigens from 100,000 cell 
YUMMER1.7 vaccinated mice can then be tested using tetramer based assays with the 
predicted epitopes. For example, Gubin et al. utilized a similar method to identify two mutant 
antigens responsible for rejection of sarcoma tumors upon treatment with anti-PD-1 (57). 
They discovered that tumor-infiltrating CD8 T cells bound to fluorescently labeled tetramers 
loaded with these two peptides and that T cells from the spleens of mice that had rejected the 
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tumors produced IFN-γ when co-cultured with the mutant epitopes. These peptides were then 
used as vaccines, which protected against tumor outgrowth when administered 
prophylactically or after tumor implantation.  
Cancer vaccines have long been promising as an additional weapon in the 
immunotherapy arsenal. However, numerous cancer vaccine trials have failed in the past 
perhaps due to an over-reliance on surrogate and subjective endpoints from preclinical 
studies such as histologic evidence of tumor necrosis or lymphocyte infiltration rather than 
objective cancer regressions (58). Rosenberg and colleagues estimated an objective response 
rate of only 2.6% in clinical trials using cancer vaccines in 440 patients (422 had metastatic 
melanoma) at the National Cancer Institute. However, the peptide vaccines given consisted 
mostly of melanoma-differentiation antigens (e.g. MART-1, gp100, tyrosinase TRP-2) or 
cancer-testes antigens (e.g. NY-ESO-1, MAGE-12, Her2/neu, telomerase proteins), not 
neoantigens. Although some of these previous trials generated high frequencies of antigen 
reactive T cells, low avidity for these self-antigens due to central tolerance may have limited 
the anti-tumor activity. Having demonstrated YUMMER1.7’s immunogenicity and the 
immune-mediated durable regression of established tumors, we believe YUMMER1.7 to be 
an appropriate model to investigate the value of neoantigen-based vaccines. 
Collectively, our findings point toward a highly immunogenic composition of 
immune infiltration within YUMMER1.7 tumors. The presence of a functional, activated T 
cell population in tumors make YUMMER1.7 a valuable tool for studying modifiers of the 
immune system such as immune checkpoint inhibitors and other therapeutics. Immune 
checkpoint blockade with ipilimumab, nivolumab and pembrolizumab has led to tumor 
regression and prolonged overall survival in patients with advanced melanoma and other 
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malignancies (28, 59). To validate YUMMER1.7 as a model for evaluating immune 
therapies, we treated 500,000 cell YUMMER1.7 tumors with anti-CTLA-4 and anti-PD-1 
therapy. When administered individually or as a combination, these treatments not only 
inhibited tumor growth but also induced regression and cure of melanoma in a proportion of 
mice. The combination of anti-CTLA-4 and anti-PD-1 did not significantly delay tumor 
growth in the less immunogenic YUMM1.7 model. CTLA-4 is believed to regulate immune 
responses by outcompeting CD28 for their ligands, CD80 and CD86, preventing adequate 
costimulation of naïve T cells (23). Because CD4 and CD8 T cells are able to infiltrate 
YUMMER1.7 tumors to a greater extent than in YUMM1.7 tumors, blockade of CTLA-4 
may have a stronger effect in the former model. In fact, the density of tumor infiltrating CD8 
T cells is one of the best predictors of response to anti-CTLA-4 (60). If the neoantigens in 
YUMM1.7 do not bind MHC complexes with high affinity, enhanced costimulation may be 
insufficient to produce an antitumor response. CTLA-4 blockade may also impair 
immunosuppressive effects of Foxp3+ regulatory T cells in YUMMER1.7 tumors. CTLA-4 
has been shown to be constitutively expressed on regulatory T cells and critical for their 
function (61, 62). Moreover, we observed increased PD1+ TIGIT+ CD8 T cells in 
YUMMER1.7, reflecting either an activated or exhausted state of cytotoxic T cells. PD-1 
blockade may exert its effect by reversing the exhausted subset by inhibiting downstream 
signaling of the PD-1 receptor and recruitment of the phosphatase SHP-2. YUMMER1.7 
demonstrates how immune therapies may shift the balance between immune surveillance and 
cancer cell growth.  
Although responses to checkpoint blockade are often durable and last for years, 
acquired resistance to these treatments has been documented (63, 64). Several studies suggest 
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that loss of beta-2-microglobulin, a component of MHC class I molecules, or downregulation 
of antigens through epigenetic regulation or selection of tumor subclones are potential 
mechanisms of acquired resistance (65-68). In a recent report, four paired tumor samples 
(before therapy and after disease progression) that exhibited late acquired resistance after 
more than 6 months of partial tumor response despite continuous anti-PD-1 therapy were 
exome sequenced (69). In one tumor pair, a homozygous frame-shift deletion in exon 1 of 
beta-2-microglobulin caused loss of plasma membrane localization of MHC class I heavy 
chains in the relapsed tumor. YUMMER1.7 is an ideal model for addressing cancer 
immunoediting and acquired resistance to therapy. Employing CRISPR/Cas9, beta-2-
microglobulin or immunogenic epitopes can be knocked down in YUMMER1.7 tumors to 
reduce immunogenicity. And inducible forms of CRISPR/Cas9 technology could allow for 
modulation of the anti-tumor response during treatment through precise temporal control of 
gene expression (70).   
Last of all, the YUMMER1.7 cell line can be used for the evaluation of promising 
immunotherapies still in development. For example, other T cell inhibitory receptors 
including LAG-3, TIM-3, VISTA and stimulatory receptors ICOS, OX40, 4-1BB are 
potential targets. Additional therapies focusing on innate immune activation such as CD40 
and STING (stimulator of interferon genes) agonists have drawn great interest. CD40 plays a 
role in the maturation of antigen presenting cells as well as B cell activation, whereas STING 
is a cytosolic DNA/damage-associated molecular pattern (DAMP) sensing pathway that 
drives type I interferon production and activation of Batf3 dendritic cells, which can cross-
present to cytotoxic CD8 T cells (71, 72). Similarly, since CSF-1R inhibition is believed to 
deplete immunosuppressive tumor-associated macrophages in tumors, we presented 
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preliminary data here that supports the beneficial effect of combining PD-L1 and CSF-1R 
inhibitors in YUMMER1.7. With no shortage of immunotherapies in the pipeline, a mouse 
melanoma model that is experimentally tractable for preclinical testing is critical.  
For all of these reasons, we anticipate that YUMMER1.7 will serve the scientific 
community well and be a valuable addition to the YUMM series. It illustrates the role that 
antigen burden plays in dictating the extent of the anti-tumor immune response and offers the 
opportunity to study the immune microenvironment with the goal of developing novel 
immunotherapies. Finally, the described approach used to enhance immunogenicity of the 
YUMM1.7 line could also be applied to other syngeneic mouse models of cancer.  
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